Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ. Gabay C, et al. Ann Rheum Dis. 2018 Jun;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608. Epub 2018 Feb 22. Ann Rheum Dis. 2018. PMID: 29472362 Free PMC article. Clinical Trial.
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol.
Mueller RB, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Mueller RB, et al. J Clin Med. 2019 Mar 3;8(3):302. doi: 10.3390/jcm8030302. J Clin Med. 2019. PMID: 30832414 Free PMC article.
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.
Kedor C, Listing J, Zernicke J, Weiß A, Behrens F, Blank N, Henes JC, Kekow J, Rubbert-Roth A, Schulze-Koops H, Seipelt E, Specker C, Feist E. Kedor C, et al. Ann Rheum Dis. 2020 Aug;79(8):1090-1097. doi: 10.1136/annrheumdis-2020-217155. Epub 2020 May 13. Ann Rheum Dis. 2020. PMID: 32404342 Free PMC article. Clinical Trial.
The virtual fishbowl: bringing back dynamic debates to medical conferences.
Muehlensiepen F, Mucke J, Krusche M, Kurkowski S, Bendzuck G, Koetter I, Lemarié V, Grahammer M, Heinze M, Schulze-Koops H, Knitza J. Muehlensiepen F, et al. Ann Rheum Dis. 2021 May;80(5):675-676. doi: 10.1136/annrheumdis-2020-219552. Epub 2020 Dec 15. Ann Rheum Dis. 2021. PMID: 33323355 No abstract available.
Digital Health Transition in Rheumatology: A Qualitative Study.
Mühlensiepen F, Kurkowski S, Krusche M, Mucke J, Prill R, Heinze M, Welcker M, Schulze-Koops H, Vuillerme N, Schett G, Knitza J. Mühlensiepen F, et al. Int J Environ Res Public Health. 2021 Mar 5;18(5):2636. doi: 10.3390/ijerph18052636. Int J Environ Res Public Health. 2021. PMID: 33807952 Free PMC article.
320 results